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WHERE DID THE TIME GO?: TEMPORAL UNCERTAINTY IN COST-
EFFECTIVENESS DECISION MODELS
Mahon R1, Manca A2, Palmer S1
1University of York, York, North Yorkshire, UK, 2University of York, Heslington, York, UK
OBJECTIVES: Since the required time horizon in a cost effectiveness decision
model often exceeds the evidence time horizon, numerous temporal uncertainties
arise regarding model parameters and structures. The objective of this study is to
demonstrate, through a motivating example: (i) why temporal uncertainty ought to
be addressed more thoroughly than it has been to date; (ii) how this uncertainty
might be expressed in decision models; and (iii) the consequences for the cost-
effectiveness results when temporal uncertainty is incorporated into the analysis.
METHODS: Taking the example of a decision model seeking to estimate the cost-
effectiveness of an early interventional strategy for patients with non-ST-elevation
acute coronary syndrome, we firstly highlight the model components that are ex-
posed to temporal uncertainty. Focusing on two key model parameters, we explore
the extent to which the existing short-term evidence could reasonably be extrap-
olated over time. We then suggest a means to quantitatively convey the temporal
uncertainty pertaining to these parameters within the model. RESULTS: Temporal
uncertainty is shown to have a significant impact on the cost-effectiveness results.
Value-of-Information analysis (specifically population EVPPI) suggests that for this
example, it may have been more cost-effective to delay adoption recommendation
until further evidence on the temporal behaviour of parameters was collected.
CONCLUSIONS: Temporal uncertainty, though rarely formally modelled, is a sig-
nificant characteristic of cost-effectiveness decision models. It is possible and de-
sirable to express temporal uncertainty within a decision model, as the complete
model may show that it is more cost-effective to collect further information on the
temporal behaviour of model parameters before issuing an adoption recommen-
dation.
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COST EFFECTIVENESS OF DABIGATRAN ETEXILATE FOR PREVENTION OF
STROKE AND SYSTEMIC EMBOLISM IN NONVALVULAR ATRIAL FIBRILLATION
PATIENTS IN THE TURKISH HEALTH CARE SETTING
Kececioglu S, Ulus P, Cukadar F
Boehringer Ingelheim Turkey, ISTANBUL, TURKEY, Turkey
OBJECTIVES: To investigate the cost-effectiveness of dabigatran etexilate (dabiga-
tran 150MG) in the Turkish health care setting. METHODS: A model was con-
structed to assess the cost-effectiveness of dabigatran versus warfarin. Direct cost
of events (stroke, intracranial bleeding), physician visits, INR tests, medication and
patients’ hospital transfers were considered. Outcome measure is defined as the
total number of events prevented per year for a population of 1000 patients.
RESULTS: For a cohort of 1,000 patients, total cost of stroke in the warfarin arm was
468,672 TL/year and in the dabigatran arm 322,212 TL/year. Cost for intracranial
bleeding events was 234,336 TL/year and 87,876 TL/year for warfarin and dabiga-
tran, respectively. Total treatment cost in the warfarin arm was 1,395,693 TL/ year
and in the dabigatran arm 1,654,728 TL/ year. The ICER for dabigatran was 25,903
TL/stroke prevented (Cost per stroke event is given as 29.292 TL in current the
Turkish health care setting). CONCLUSIONS: A major limitation of this analysis is
that it doesn’t account for disability costs, which are other major direct costs of the
Turkish Social Security Institution. According to the World Health Organization, for
counties where a willingness to pay threshold for ICERs doesn’t exist, such as in
Turkey, ICERs remaining below 1-3 times of the GDP per capita per unit of health
gain are deemed acceptable. Dabigatran can be considered cost-effective with an
ICER per stroke avoided below the GDP per capita (31,280 TL estimated for 2012)
when compared to current standard of care in Turkey, which is warfarin.
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PHARMACOECONOMIC EVALUATION OF OLMESARTAN, LOSARTAN AND
VALSARTAN IN TREATMENT OF ESSENTIAL ARTERIAL HYPERTENSION
Gorokhova SG, Ryazhenov VV
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
OBJECTIVES: Olmesartan medoxomil is one of the latest angiotensin II receptor
blockers (ARB) approved for use in the Russian Federation. The objective was to
assess cost-effectiveness of olmesartan compared with losartan and valsartan in
adult patients with mild and moderate essential arterial hypertension. METHODS:
The study was performed by modeling and cost-effectiveness analyses. We have
also assessed cost-effectiveness ratio (CER) growth rate, which represents the rel-
ative rate of change in value for the analyzed periods. Analyzed costs included
brand drugs only. Efficacy data were obtained from a head-to-head clinical trial, in
which office blood pressure rate, number of patients with mild and moderate ar-
terial hypertension achieving target blood pressure in weeks 4, 8, and 12 were taken
into account. Patients with diabetes mellitus and chronic renal failure were ana-
lyzed separately. The time horizon of the analysis was 12 weeks. Pairwise compar-
ison of costs, CER, CEAincr and CER growth rate were performed separately for
olmesartan vs. losartan, and olmesartan vs. valsartan. RESULTS: Treatment with
olmesartan provides more clinical effect for less costs and demonstrates better
cost-effectiveness ratio than losartan or valsartan in terms of target BP after 12
weeks. In both pairs, CER growth rate was minimal in case of olmesartan; this
reflects the dynamics of this value during treatment. Similar results were obtained
for comparable ARBs in patients with diabetes mellitus and renal failure.
CONCLUSIONS: Cost-effectiveness analysis shows that treatment of mild arterial
hypertension with olmesartan is more appropriate from the pharmacoeconomic
point of view than losartan and valsartan, both in general group and in patients
with diabetes mellitus and renal failure.
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CLINICAL AND ECONOMIC ANALYSIS OF THE EFFECTIVENESS OF
ANTIHYPOXIA SUBSTANCE POLYDIHYDROXYPHENYLENETHIOSULFONATE
SODIUM (HYPOXENUM) IN THE COMPLEX ANGINA PECTORIS TREATMENT
Vorobiev P, Luneva A
Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia
OBJECTIVES: To evaluate the economic feasibility of using Hypoxenum in compar-
ison to not administering it, in the complex treatment of angina pectoris.
METHODS: A randomized prospective controlled study on typical practice of 200
patients who received comprehensive treatment of angina pectoris with or without
Hypoxenum, was performed to assess direct medical costs and cost effectiveness
ratio. RESULTS: Overall cost of treatment of one patient with angina pectoris
within 15 days in the hospital with Hypoxenum in the combined therapy was 5
968.94 rubles. The total cost of treatment of one patient in group of typical treat-
ment of angina pectoris was 5 294.10 rubles. As the criteria of the effectiveness of
treatment were taken: indicators of performed work, threshold power, exercise
tolerance test. At the end indicators of the Hypoxenum group and the typical
practice group were: work performed: increased of 25.9 kJ and 15.1 kJ, respectively
(differences were significant, p0.05), the threshold power was 25.5 Watt and 13,2
Watt, respectively. Increased exercise tolerance was observed in 49% of patients in
the Hypoxenum group and in 28% of patients in the control group. The cost- effec-
tiveness ratio for the criterion of completed work was 230.4 rubles and 350.6 rubles,
for threshold power - 234.07. and 401.06 rubles, for increasing of exercise tolerance
- 12 181.51 rubles and 18 907.50 rubles for Hypoxenum and typical practice,
respectively. CONCLUSIONS: The cost-effectiveness study on the dynamics of tol-
erance of exercise compared to typical practice, revealed that treatment of angina
pectoris, with Hypoxenum is a clinically and economically feasible.
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COST-EFFECTIVENESS OF TICAGRELOR IN THE MANAGEMENT OF ACUTE
CORONARY SYNDROMES IN BELGIUM
Chevalier P1, Lamotte M1, Petit C2
1IMS Health, Vilvoorde, Belgium, 2AstraZeneca, Brussels, Belgium
OBJECTIVES: A randomized phase-III clinical trial (PLATO) showed that a 1-year
dual antiplatelet treatment with ticagrelor and aspirin (ASA) reduced the compos-
ite endpoint of cardiovascular death, myocardial infarction (MI), and stroke with-
out an increase in major bleedings compared to the combination clopidogrel-ASA
in patients with acute coronary syndromes (ACS). Using a model based on the
PLATO outcomes, we assessed the cost-effectiveness of ticagrelor-ASA vs. clopi-
dogrel-ASA in ACS patients in Belgium. METHODS: The model developed in Tree-
Age combined a decision tree for the first year of treatment and a Markov model
with a lifelong time horizon using 1 year cycles. First year probabilities of events
(cardiovascular death, MI, strokes, bleedings) were derived from the PLATO study.
In subsequent years, transition probabilities between health states (event-free,
post-MI, post-stroke, death) were obtained from a previously published HTA-
model on clopidogrel-ASA in ACS. Utility data was provided by literature. Cost data
was obtained from published articles and from the IMS Hospital Disease Database,.
The incremental cost-effectiveness ratio (ICER) of ticagrelor vs. generic clopidogrel
was calculated in terms of cost per quality-adjusted life-year (QALY) gained over a
lifetime horizon from the Belgian payer perspective and evaluated against the
lower WHO threshold based on 1 time the Gross Domestic Product for Belgium
(around 30,000€/QALY). Annual discounting rates of 3% and 1.5% were applied on
costs and effects respectively. RESULTS: Ticagrelor-ASA was associated with an
incremental cost of €816.9 and 0.079 added QALY’s (primarily driven by a reduction
in MI and mortality). The ICER was 10,316€/QALY. The cost per life year gained was
6,965€. The ICERs were consistent in subgroups of patients treated invasively or
not. Probabilistic sensitivity analysis showed that the ICER remained below
30,000€/QALY in 98.8% of cases (also in subgroups). CONCLUSIONS:Dual antiplate-
let treatment with ticagrelor-ASA can be considered cost-effective compared to
clopidogrel-ASA.
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A HEALTH ECONOMIC EVALUATION OF OMEGA-3 ACID ETHYL ESTERS 90 IN
THE SECONDARY PREVENTION POST-MI
Gerlier L1, Vellopoulou K1, Lamotte M1, Lacey L2, Einroos A3, Carr E4
1IMS Health, Vilvoorde, Belgium, 2Lacey Solutions Ltd, Skerries, Ireland, 3Abbott Laboratories,
Tallinn, Estonia, 4Abbott Laboratories, Allschwil, Switzerland
OBJECTIVES: Adding omega-3 acid ethyl esters 90 (O-3EE) to standard therapies in
secondary prevention after post myocardial infarction (MI) significantly reduces
sudden death. This study evaluates the cost-effectiveness of adding 1g O-3EE to
current secondary prevention treatment after acute MI in the Irish and Estonian
public health care systems. METHODS: Based on GISSI-Prevenzione trial outcomes
(MI, stroke, revascularisation rate, mortality), two models for Ireland and Estonia
were developed, using a lifetime and 3.5-years (GISSI-Prevenzione trial duration)
time horizons with 1-year cycles. Local event costs were based on AR-DRGs (Ire-
land) and NordDRGs tariffs (Estonia). Life expectancy data (12.9 years) for survivors
of cardiac disease (15,590 cases) were obtained from the Saskatchewan database
and country-adjusted. Annual discounting of 4% (Ireland) and 5% (Estonia) was
applied on outcomes and costs. Incremental cost (€) per life year gained (LYG) and
Quality of Adjusted Life years Gained (QALYG) were calculated from the public
payer perspective. RESULTS: Lifelong treatment with O-3EE yielded 0.26 LYG, 0.19
QALYG (Ireland) and 0.24 LYG (Estonia) with an additional total direct cost of €1,624
(Ireland) and €1,218 (Estonia) resulting in an incremental cost-effectiveness ratio
(ICER) of €6,223/LYG and €8,210/QALYG (Ireland) and €5,079/LYG (Estonia). Respec-
tive ICERs at 3.5-years were €18,686/LYG, €23,527/QALYG for Ireland and €28,797/
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LYG for Estonia. Sensitivity analyses showed that time horizon, discounting and
follow-up cost of stroke are sensitive factors. Difference in co-payment for workers
and retired patients (Estonia) marginally impacted ICERs. Probabilistic sensitivity
analysis showed that the probability for O-3EE to be cost-effective is higher than
95% in Estonia (threshold €32,000/LYG). One-way sensitivity analyses showed
strong robustness in Ireland (threshold €20,000/QALY). CONCLUSIONS: The incre-
mental cost-effectiveness ratios indicated that adding 1g O-3EE to standard treat-
ment in secondary prevention post-MI was in the range likely to be considered
cost-effective in Ireland and Estonia.
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PHARMACOECONOMIC ANALYSIS OF AZILSARTAN MEDOXOMIL IN PATIENTS
WITH ARTERIAL HYPERTENSION: COMPARISON WITH VALSARTAN,
TELMISARTAN, LOSARTAN AND IRBESARTAN IN THE MEXICAN CONTEXT
Zamora Muciño-Arroyo AJ1, Gay-Molina JG2, Chiu-Ugalde J3, Figueroa-Rodriguez A3,
Arellano Plancarte A3, López-Alvarenga JC4, Sánchez-Kobashi R2, Vargas JA3
1Hospital Cardiológica, Aguascalientes, Ags., Mexico, 2Tecnología e Informática para la Salud,
S.A. de C.V., Mexico City, Mexico, 3Nycomed: A Takeda Company, Naucalpan, Edo. México,
Mexico, 4Hospital General de México O.D., Mexico City, Mexico
OBJECTIVES: To compare the incremental cost-effectiveness ratio (ICER) and in-
cremental cost-utility ratio (ICUR) of the angiotensin II receptor antagonist Azilsa-
tan vs current treatments of the same drug class as valsartan, telmisartan, losartan
and irbesartan. METHODS: Cost-effectiveness and cost-utility analysis were con-
ducted using a Markov model with a 35-year temporal horizon for patients over the
age of 45 and diagnosed with systemic arterial hypertension to calculate the ICERs
of each treatment. The model adopts the Mexican public health institutions’ per-
spective. Four health states were incorporated: alive and healthy, hypertensive
with non-fatal acute myocardial infarction (AMI), hypertensive with non-fatal
stroke and death. Transition probabilities were calculated based on the national
risk of having a stroke or AMI and the probability of having a vascular complication
depending on blood pressure levels (in mmHg). Costs and effectiveness data were
taken from health institutions, producer pharmaceutical companies or extracted
from published literature. Outcome measures included ICER and ICUR. Cost-effec-
tiveness was determined according to the 1GDP/capita threshold established by
the National Health Council in Mexico. RESULTS: Azilsartan was found to be dom-
inant when compared with telmisartan, valsartan and irbesartan. Azilsartan was
also more effective when compared with losartan (10.76 vs. 10.47 life years gained)
although more costly (USD$ 6,118.92 vs. USD$ 5,192.71). The ICER was USD$
3,202.84 per life year gained. According to the cost-utility analysis, the ICUR per
quality-adjusted life year gained was USD$ 3,458.09. CONCLUSIONS: The ICER and
ICUR are well below 1GDP (USD$ 9,350.07) per capita versus losartan. Both azilsar-
tan and losartan were found to be dominant in comparison with the other included
treatments. Azilsartan is therefore a very cost-effective intervention for the Mexi-
can population over 45 with systemic arterial hypertension.
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MIND THE GAP! GEOGRAPHIC TRANSFERABILITY OF ECONOMIC EVALUATION
IN HEALTH
Boehler CEH, Buxton M, Lord J
HERG, Brunel University, Uxbridge, UK
OBJECTIVES: Transferring cost-effectiveness information between geographic do-
mains offers the potential for more efficient use of analytical resources. However,
it is difficult for decison makers to know when they can rely on cost-effectiveness
evidence produced for another context. This paper explores the transferability of
economic evaluation results produced for one geographic area to another location
of interest, and outlines an approach to identify factors to predict when this is
appropriate. METHODS: We developed multilevel statistical models for the inte-
gration of published cost-effectiveness data to assess the impact of contextual
effects on country level; whilst controlling for baseline characteristics within, and
across, a set of economic evaluation studies. Explanatory variables were derived
from a list of factors suggested in the literature as possible constraints on the
transferability of cost-effectiveness evidence. We illustrated our approach using
published estimates of the cost-effectiveness of statins for the primary and sec-
ondary prevention of cardiovascular disease (CVD). 2094 estimates of the costs and
effects of statins were abstracted from 67 studies related to 23 geographic domains,
together with covariates on data, study and country level. RESULTS: The propor-
tion of variation at the country-level observed depends on the appropriate multi-
level model structure and never exceeds 15% for incremental effects and 21% for
incremental cost respectively. Key sources of variability are patient and disease
characteristics, intervention cost and a number of methodological characteristics
defined on the data level. There were fewer significant covariates on the study and
country levels. CONCLUSIONS: Our analysis suggests that variability in cost-effec-
tiveness data is primarily due to differences between studies, not countries. Fur-
ther, comparing different models suggests that data from multinational studies
severely underestimates country-level variability. Additional research is needed to
test the robustness of these conclusions on other sets of cost-effectiveness data,
and to further explore the appropriate set of covariates.
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ECONOMIC EVALUATION OF INITIATION WITH ENDOTHELIN RECEPTOR
ANTAGONISTS IN THE TREATMENT OF PULMONARY ARTERIAL
HYPERTENSION IN SPAIN
Villa G1, Escribano P2, Gil J3, Roman A4, Morano R1
1GlaxoSmithKline, Madrid, Spain, 2Hospital Universitario 12 de Octubre, Madrid, Spain,
3Hospital General Universitario de Alicante, Alicante, Spain, 4Hospital Universitari Valle
d’Hebron, Barcelona, Spain
OBJECTIVES: To evaluate health outcomes and costs of initiation with endothelin
receptor antagonists [ERA] monotherapy (ambrisentan or bosentan) followed by
sequential combination with phosphodiesterase-5 inhibitors [PDE-5] and prostan-
oids in the treatment of pulmonary arterial hypertension in Spain. METHODS: A
Markov model was developed based on New York Hearth Association functional
classes. Transition probabilities [TP] for ERA initiation were gathered from the
pivotal clinical trials. Outcomes were measured in quality-adjusted life years
[QALY]. A panel of 3 independent experts reached a consensus on patient manage-
ment based on clinical practice. Patients initiated treatment with either ambrisen-
tan or bosentan, and revised treatment every 12 weeks based on their health status
and previous medication records. A National Health System perspective was ad-
opted. Pharmacological costs and costs associated with very frequent adverse
events [AE] (i.e. edema and hepatic abnormalities) were included. Following a first-
order Monte Carlo simulation approach, 1,000 hypothetical patients were observed
in a temporal horizon of 60 weeks. This simulation was repeated 1,000 times.
RESULTS: Average (per-patient and year) pharmacological costs [95% CI] were
€35,550 [€34,944-€36,196] and €40,224 [€39,264-€41,212] for initiation with ambrisen-
tan and bosentan, respectively. Average costs associated with AE management
were €117 [€110-€124] and €171 [€160-€182], respectively. No clinically relevant dif-
ferences in average QALY were found: 0.6853 [0.6836-0.6870] and 0.6903 [0.6885-
0.6921], respectively. This agrees with published meta-analyses and a priori expert
judgment. Initiation with ambrisentan would bring about cost savings of €4,727
[€3,903-€5,620]. From a cost-minimization perspective, if the same TP were consid-
ered for both initiation alternatives, initiation with ambrisentan would provide
cost savings of €4,952 [€4,898-€5,007] (using ambrisentan’s TP) and €4,770 [€4,718-
€4,819] (using bosentan’s TP). CONCLUSIONS: Initiation with ambrisentan mono-
therapy followed by sequential combination with PDE-5 and prostanoids yields
comparable outcomes at lower costs than initiation with bosentan. These results
might be considered in hospital pharmacy budget allocation decision making.
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ECONOMIC EVALUATION OF THROMBO INCODE, A GENETIC PLATFORM FOR
THE ASSESSMENT OF VENOUS THROMBOEMBOLISM (VTE) RISK IN PATIENTS
WITH A PATTERN OF VTE OR A CONDITION THAT SUGGESTS A HEREDITARY
COMPONENT
Marrugat J1, Elosúa R1, Coca A2, de la Figuera M3, Rubio-Terrés C4, Rubio-Rodríguez D5,
Ramírez de Arellano A6, Boldeanu A6, Puig-Gilberte J7, Salas E7
1IMIM-Hospital del Mar, Barcelona, Spain, 2Hospital Clínic, Barcelona, Spain, 3CAP Cerdenya,
Barcelona, Spain, 4HealthValue, Madrid, Spain, 5Health Value, Madrid, Spain, 6FERRER-inCode,
Barcelona, Spain, 7GENDIAG, Barcelona, Spain
OBJECTIVES: To conduct an economic analysis of the risk assessment of VTE with
Thrombo inCode, a genetic platform, in patients with a pattern of VTE or a condi-
tion that suggests a hereditary component, compared with the standard methods
so far used (Factor V Leiden and prothrombin G20210A mutation). METHODS: A
Markov model was developed with 7 states of health (thrombophilia, no thrombo-
philia, VTE, major bleeding, intracranial hemorrhage, no intracranial hemorrhage,
and death). The predictive ability of VTE from the identification of thrombophilia
with Thrombo inCode and the standard method, was obtained from three studies
of the method validation performed in three different populations (3,661 patients
in total). It was assumed that patients with thrombophilia positively identified
undergo a preventive treatment of VTE, which involves both reducing the number
of VTE as the increase in major bleeding. The utilities and costs of Markov states
were obtained from the literature and Spanish sources. The analysis was done
from the National Health System perspective, for a time horizon of 5 years and
lifetime. An annual discount rate of 3.5% for costs and benefits was applied.
RESULTS: For a Thrombo inCode price of 290 €, this genetic platform would be the
dominant option for any time horizon from 5 years. The threshold price of
Thrombo inCode to reach the incremental cost-effectiveness ratio (ICER) threshold
generally accepted in Spain (30,000 €/QALY) would range between € 1,069 and €
1,284. Probabilistic analyses indicate that Thrombo inCode assessment is domi-
nant in the 97.2 to 98.6% of the tests, according to the selected population.
CONCLUSIONS: Thrombo inCode is a cost-effective genetic option in VTE risk as-
sessment compared with the standard method.
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COST-EFFECTIVENESS OF SMOKING CESSATION INTERVENTIONS IN SMOKERS
WITH CARDIOVASCULAR DISEASE IN THE NETHERLANDS
Majer IM1, Rozenbaum MH2, Verheggen B1
1Pharmerit International, Rotterdam, Zuid-Holland, The Netherlands, 2Pfizer Nederland, Capelle
aan den Ijseel, Zuid-Holland, The Netherlands
OBJECTIVES: Limited pharmaceutical options are available for smoking cessation
interventions for smokers with a history of cardiovascular disease (CVD) in the
Netherlands. The objective of our study was to assess the cost-effectiveness of
varenicline versus nicotine replacement therapy (NRT) in such a population.
METHODS: A lifetime horizon Markov model was developed to compare the cost-
effectiveness of smoking cessation therapies from the health care provider per-
spective. Efficacy data (continuous abstinence rates) for each therapeutic option
was obtained from an indirect comparison of available clinical trials. The popula-
tion of smokers with cardiovascular disease was divided into three cohorts: those
with a history of coronary heart disease (CHD), stroke and peripheral vascular
disease (PVD). In the model, the cohorts are followed as they progress through
potential disease states including CHD, stroke, PVD, COPD, mouth cancer and lung
cancer. Transition probabilities depend on age (35-65, 65), gender and smoking
status (current, former or never smoker) allowing for variations in the patient
populations. Following the Dutch pharmacoeconomic research guideline, costs
and effect were discounted at 4% and 1.5%, respectively. Univariate and probabi-
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